Treatment of recurrent high grade gliomas with GliaSite® brachytherapy: Preliminary results

C. Gobitti, E. Borsatti, M. Arcicasa, M. Roncadin, G. Franchin, M. Skrap, B. Zanotti, F. Tuniz, A. Verlicchi, A. Cramaro, M. Cimitan, R. Ruffo, E. Capra, A. Drigo, M. C. Decolle, S. D'Agostini, M. G. Trovò

Research output: Contribution to journalArticlepeer-review


Despite macroscopically radical surgery and combined adjuvant chemoradiation recurrence of malignant glioma remains a certainty. About 80% of patients experience a tumor recurrence within 2 cm of the resection margin. Only a select group of patients with recurrent malignant gliomas are candidates for reoperation, but in spite of further adjuvant therapy, long-term survival is rare. The GliaSite® RTS was developed in an attempt to allow an additional radiation dose to be delivered in a way that maximizes the patient's quality of life while delivering a radiation dose to the tissue at greatest risk of recurrence. This study reports our experience with GliaSite® on 12 patients with recurrent high grade gliomas. The median radiation dose delivered was 46.5 Gy (range 45-60 Gy) to an average depth of 1 cm from the surgical cavity wall. Mild side effects post lotrex infusion were easily managed with drug therapy. One case of late symptomatic radiation necrosis was pathologically documented and a second case radiologically suspected. At the time of this analysis (median follow up 8.4 months, range 1-14 months) two patients died after 12 months from GliaSite® treatment for disease progression. These preliminary data need to be confirmed by a larger patient population with more information on the progression-free survival and overall survival. Our preliminary results confirm that brachytherapy treatment with GliaSite® is safe, improves quality of life and reduces the radiation adverse effects versus external beam radiotherapy.

Original languageEnglish
Pages (from-to)135-143
Number of pages9
JournalRivista Medica
Issue number4
Publication statusPublished - Dec 2007


  • Brachytherapy
  • GliaSite®
  • High grade gliomas
  • Recurrence

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Treatment of recurrent high grade gliomas with GliaSite® brachytherapy: Preliminary results'. Together they form a unique fingerprint.

Cite this